Clinical genetics of hereditary colorectal cancer

Hematology/Oncology Clinics of North America

Volumn 24, Issue 5, 2010, Pages 837-859

  Power, Derek G ^a   Gloglowski, Emily ^a   Lipkin, Steven M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Colorectal cancer; Genetics; Germline; Hereditary; Lynch syndrome; Mismatch repair

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2;

ADENOMATOUS POLYP; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; COLORECTAL ADENOMA; COLORECTAL CANCER; COWDEN SYNDROME; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; HYPERPLASTIC POLYPOSIS; ILEORECTAL ANASTOMOSIS; IMMUNOHISTOCHEMISTRY; JUVENILE POLYP; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISSENSE MUTATION; POLYPOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TOTAL COLON RESECTION;

CLINICAL MEDICINE; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PEUTZ-JEGHERS SYNDROME;

EID: 77956306344     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.06.006     Document Type: Review

References (134)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Kastrinos F., Syngal S. Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol 2007, 34:418-424.
4. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348:919-932.
5. Fuchs C.S., Giovannucci E.L., Colditz G.A., et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994, 331:1669-1674.
6. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460.
7. Offit K. MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie. J Clin Oncol 2004, 22:4449-4451.
8. Plaschke J., Engel C., Kruger S., et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004, 22:4486-4494.
9. Senter L., Clendenning M., Sotamaa K., et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008, 135:419-428.
10. Liu H.X., Zhou X.L., Liu T., et al. The role of hMLH3 in familial colorectal cancer. Cancer Res 2003, 63:1894-1899.
11. Nicolaides N.C., Papadopoulos N., Liu B., et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371:75-80.
12. Vasen H.F., Mecklin J.P., Khan P.M., et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425.
13. Vasen H.F., Watson P., Mecklin J.P., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116:1453-1456.
14. Palomaki G.E., McClain M.R., Melillo S., et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009, 11:42-65.
15. Green R.C., Parfrey P.S., Woods M.O., et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009, 101:331-340.
16. Kratz C.P., Holter S., Etzler J., et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 2009, 46:418-420.
17. Jass J.R. Familial colorectal cancer: pathology and molecular characteristics. Lancet Oncol 2000, 1:220-226.
18. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
19. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
20. Hesson L.B., Hitchins M.P., Ward R.L. Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev 2010, 31:31.
21. Cunningham J.M., Christensen E.R., Tester D.J., et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998, 58:3455-3460.
22. Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010, 7:153-162.
23. Lievre A., Laurent-Puig P. Genetics: predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol 2009, 6:306-307.
24. Rajagopalan H., Bardelli A., Lengauer C., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
25. Loughrey M.B., Waring P.M., Tan A., et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007, 6:301-310.
26. Sanchez J.A., Krumroy L., Plummer S., et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009, 96:1196-1204.
27. Ogino S., Nosho K., Kirkner G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
28. Ligtenberg M.J., Kuiper R.P., Chan T.L., et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009, 41:112-117.
29. Kovacs M.E., Papp J., Szentirmay Z., et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009, 30:197-203.
30. Niessen R.C., Hofstra R.M., Westers H., et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009, 48:737-744.
31. Nagasaka T., Rhees J., Kloor M., et al. Somatic hypermethylation of MSH2 is a frequent event in lynch syndrome colorectal cancers. Cancer Res 2010, 70:3098-3108.
32. Peltomaki P., Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004, 20:269-276.
33. Wahlberg S.S., Schmeits J., Thomas G., et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002, 62:3485-3492.
34. Chao E.C., Velasquez J.L., Witherspoon M.S., et al. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat 2008, 29:852-860.
35. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-5788.
36. Mvundura M., Grosse S.D., Hampel H., et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010, 12:93-104.
37. Kambara T., Simms L.A., Whitehall V.L., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144.
38. Jensen L.H., Lindebjerg J., Byriel L., et al. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis 2008, 10:490-497.
39. Wijnen J.T., Vasen H.F., Khan P.M., et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998, 339:511-518.
40. Barnetson R.A., Tenesa A., Farrington S.M., et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006, 354:2751-2763.
41. Balmana J., Stockwell D.H., Steyerberg E.W., et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006, 296:1469-1478.
42. Chen S., Wang W., Lee S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006, 296:1479-1487.
43. Marroni F., Pastrello C., Benatti P., et al. A genetic model for determining MSH2 and MLH1 carrier probabilities based on family history and tumor microsatellite instability. Clin Genet 2006, 69:254-262.
44. Hendriks Y.M., Wagner A., Morreau H., et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127:17-25.
45. Wagner A., Hendriks Y., Meijers-Heijboer E.J., et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001, 38:318-322.
46. Buttin B.M., Powell M.A., Mutch D.G., et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004, 74:1262-1269.
47. Vasen H.F., Moslein G., Alonso A., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007, 44:353-362.
48. Lindor N.M., Petersen G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296:1507-1517.
49. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-1595.
50. de Jong A.E., Hendriks Y.M., Kleibeuker J.H., et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006, 130:665-671.
51. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58:130-160.
52. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006, 24:4642-4660.
53. de Vos tot Nederveen Cappel W.H., Nagengast F.M., Griffioen G., et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002, 45:1588-1594.
54. Van Dalen R., Church J., McGannon E., et al. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum 2003, 46:617-620.
55. You Y.N., Chua H.K., Nelson H., et al. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum 2008, 51:1036-1043.
56. Maeda T., Cannom R.R., Beart R.W., et al. Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. J Clin Oncol 2010, 28:1175-1180.
57. de Vos tot Nederveen Cappel W.H., Buskens E., van Duijvendijk P., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003, 52:1752-1755.
58. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
59. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
60. Malesci A., Laghi L., Bianchi P., et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007, 13:3831-3839.
61. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.
62. Roth A.D., Tejpar S., Delorenzi M., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
63. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
64. Liang J.T., Huang K.C., Lai H.S., et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002, 101:519-525.
65. Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials [abstract #4008]. American Society of Clinical Oncology Annual Meeting 2008.
66. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia Group B Protocol 89803. J Clin Oncol 2009, 27:1814-1821.
67. Kim S.T., Lee J., Park S.H., et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2009, 24:24.
68. Vilar Sanchez E, Chow A, Raskin L, et al. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer [abstract #11028]. American Society of Clinical Oncology Annual Meeting 2009.
69. Burn J., Bishop D.T., Mecklin J.P., et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008, 359:2567-2578.
70. Solomon S.D., Pfeffer M.A., McMurray J.J., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006, 114:1028-1035.
71. Lee S., Hong S.W., Shin S.J., et al. Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocr J 2004, 51:317-323.
72. Giardiello F.M., Offerhaus G.J., Krush A.J., et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 1991, 119:766-768.
73. Bisgaard M.L., Bulow S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet A 2006, 140:200-204.
74. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum Mol Genet 2001, 10:721-733.
75. Goss K.H., Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000, 18:1967-1979.
76. Salahshor S., Woodgett J.R. The links between axin and carcinogenesis. J Clin Pathol 2005, 58:225-236.
77. Laurent-Puig P., Beroud C., Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998, 26:269-270.
78. Al-Sukhni W., Aronson M., Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am 2008, 88:819-844. vii.
79. Wallis Y.L., Morton D.G., McKeown C.M., et al. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999, 36:14-20.
80. Caspari R., Friedl W., Mandl M., et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet 1994, 343:629-632.
81. Houlston R., Crabtree M., Phillips R., et al. Explaining differences in the severity of familial adenomatous polyposis and the search for modifier genes. Gut 2001, 48:1-5.
82. Crabtree M.D., Tomlinson I.P., Hodgson S.V., et al. Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. Gut 2002, 51:420-423.
83. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004, 4:769-780.
84. Merg A., Lynch H.T., Lynch J.F., et al. Hereditary colorectal cancer-part II. Curr Probl Surg 2005, 42:267-333.
85. National Comprehensive Cancer Network. National Comprehensive Cancer Network - guidelines for detection, prevention, risk reduction: colorectal cancer screening; 2010.
86. Vasen H.F., Moslein G., Alonso A., et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008, 57:704-713.
87. Bulow C., Vasen H., Jarvinen H., et al. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000, 119:1454-1460.
88. Gallagher M.C., Phillips R.K. Serrated adenomas in FAP. Familial adenomatous polyposis. Gut 2002, 51:895-896. author reply 896.
89. Keller J.J., Giardiello F.M. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther 2003, 2:S140-S149.
90. Utech M., Bruwer M., Buerger H., et al. Chirurg 2002, 73:855-858. [in German].
91. Hisamuddin I.M., Wehbi M.A., Schmotzer B., et al. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2005, 14:2366-2369.
92. Giardiello F.M., Hylind L.M., Trimbath J.D., et al. Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 2005, 128:1077-1080.
93. Jones D.H., Silberstein P.T., Lynch H., et al. Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis. J Clin Oncol 2005, 23:6278-6280.
94. Knudsen A.L., Bisgaard M.L., Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003, 2:43-55.
95. Hernegger G.S., Moore H.G., Guillem J.G. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002, 45:127-134. [discussion: 134-26].
96. Soravia C., Berk T., Madlensky L., et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998, 62:1290-1301.
97. Rozen P., Samuel Z., Shomrat R., et al. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. Gut 1999, 45:829-833.
98. Lynch H.T., Smyrk T., McGinn T., et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995, 76:2427-2433.
99. Laken S.J., Petersen G.M., Gruber S.B., et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997, 17:79-83.
100. Gryfe R., Di Nicola N., Lal G., et al. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 1999, 64:378-384.
101. Jo W.S., Bandipalliam P., Shannon K.M., et al. Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol 2005, 3:1022-1028.
102. Sieber O.M., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348:791-799.
103. Jones S., Emmerson P., Maynard J., et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G: C->T: a mutations. Hum Mol Genet 2002, 11:2961-2967.
104. Croitoru M.E., Cleary S.P., Di Nicola N., et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 2004, 96:1631-1634.
105. Jenkins M.A., Croitoru M.E., Monga N., et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 2006, 15:312-314.
106. Eliason K., Hendrickson B.C., Judkins T., et al. The potential for increased clinical sensitivity in genetic testing for polyposis colorectal cancer through the analysis of MYH mutations in North American patients. J Med Genet 2005, 42:95-96.
107. Wang L., Baudhuin L.M., Boardman L.A., et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004, 127:9-16.
108. Marra G., Jiricny J. Multiple colorectal adenomas-is their number up?. N Engl J Med 2003, 348:845-847.
109. Farrington S.M., Tenesa A., Barnetson R., et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005, 77:112-119.
110. Leite J.S., Isidro G., Martins M., et al. Is prophylactic colectomy indicated in patients with MYH-associated polyposis?. Colorectal Dis 2005, 7:327-331.
111. Boardman L.A. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am 2002, 31:1107-1131.
112. Giardiello F.M., Trimbath J.D. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006, 4:408-415.
113. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447-1453.
114. Hearle N., Schumacher V., Menko F.H., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006, 12:3209-3215.
115. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 1999, 55:735-750.
116. Abdel-Rahman W.M., Peltomaki P. Molecular basis and diagnostics of hereditary colorectal cancers. Ann Med 2004, 36:379-388.
117. Boardman L.A., Couch F.J., Burgart L.J., et al. Genetic heterogeneity in Peutz-Jeghers syndrome. Hum Mutat 2000, 16:23-30.
118. Mehenni H., Blouin J.L., Radhakrishna U., et al. Peutz-Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. Am J Hum Genet 1997, 61:1327-1334.
119. Sweet K., Willis J., Zhou X.P., et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005, 294:2465-2473.
120. McGrath D.R., Spigelman A.D. Preventive measures in Peutz-Jeghers syndrome. Fam Cancer 2001, 1:121-125.
121. Saurin J.C., Delvaux M., Gaudin J.L., et al. Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: blinded comparison with video push-enteroscopy. Endoscopy 2003, 35:576-584.
122. Rustgi A.K. The genetics of hereditary colon cancer. Genes Dev 2007, 21:2525-2538.
123. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009, 11:687-694.
124. Parsons D.W., Wang T.L., Samuels Y., et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436:792.
125. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29:673-680.
126. Lipkin S.M., Afrasiabi K. Familial colorectal cancer syndrome X. Semin Oncol 2007, 34:425-427.
127. Renkonen E., Zhang Y., Lohi H., et al. Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J Clin Oncol 2003, 21:3629-3637.
128. Abdel-Rahman W.M., Ollikainen M., Kariola R., et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005, 24:1542-1551.
129. Young J., Barker M.A., Simms L.A., et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005, 3:254-263.
130. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979-1985.
131. Llor X., Pons E., Xicola R.M., et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005, 11:7304-7310.
132. Fearnhead N.S., Winney B., Bodmer W.F. Rare variant hypothesis for multifactorial inheritance: susceptibility to colorectal adenomas as a model. Cell Cycle 2005, 4:521-525.
133. Rennert G., Almog R., Tomsho L.P., et al. Colorectal polyps in carriers of the APC I1307K polymorphism. Dis Colon Rectum 2005, 48:2317-2321.
134. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009, 10:353-358.